Drug Profile
Filgrastim biosimilar - Aequus/CTI BioPharma
Alternative Names: AQB-101; Filgrastim-biosimilar-Aequus/CTI BioPharma; G-CSF-Aequus/CTI BioPharma; Granulocyte colony stimulating factorLatest Information Update: 28 Jun 2023
Price :
$50
*
At a glance
- Originator Aequus BioPharma
- Developer Aequus BioPharma; CTI BioPharma
- Class Chemoprotectants; Granulocyte colony-stimulating factors; Neuroprotectants; Recombinant proteins
- Mechanism of Action Granulocyte colony stimulating factor receptor agonists; Granulocyte colony-stimulating factor replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Neutropenia